Encorafenib plus binimetinib for BRAF V600-mutated thyroid cancer in Japan: final analysis.

Int J Clin OncolJul 31, 2026 (epub)
Clinical ResearchOncology (Medical)Open access

Iwao Sugitani, Naomi Kiyota, Hiroo Imai et al.

✦ AI-curated · Sources linked

In 30 seconds

This multicenter, open-label phase 2 trial assessed the efficacy and safety of encorafenib plus binimetinib (ENC + BIN) in 22 patients with unresectable BRAF V600-mutated thyroid cancer. The objective response rate (ORR) increased to 68.2% after a median follow-up of 28.7 months, indicating sustained tumor responses.

Key findings

  • The objective response rate (ORR) for ENC + BIN was 68.2% in patients with BRAF V600-mutated thyroid cancer.
  • Median progression-free survival (PFS) was not reached for differentiated thyroid carcinoma (DTC).
  • Median overall survival (OS) was 17.7 months for anaplastic thyroid carcinoma (ATC).
  • Common adverse events included eye disorders (5/12) and infections (4/12) after > 360 days.

Why it matters

The findings suggest that ENC + BIN may offer a viable treatment option for patients with BRAF V600-mutated thyroid cancer, particularly those who are refractory to other therapies, highlighting the need for ongoing management strategies in this population.

Source

PubMed · PMID 42536275Free full text on PubMed Central

Published in Int J Clin Oncol. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Oncology (Medical)

Clinical ResearchPreventive Medicine / Public Health

2025 National Guidelines on the Mediterranean Diet: Executive Summary of a Joint Report by Italian Scientific Societies and the National Institute of Health Task Force on Clinical Practice Guidelines.

This systematic review and practice guideline, developed by a multidisciplinary panel using NUTRIGRADE, assessed Mediterranean diet evidence across nine health domains and one economic domain.

Nutr RevNov 12, 2026Read summary
Clinical ResearchOrthopedic Surgery

Prevention of Venous Thromboembolism after Total Hip or Knee Replacement.

This multicenter randomized comparative-effectiveness noninferiority trial compared 30 days of aspirin, warfarin, or rivaroxaban for VTE prophylaxis after elective total hip or knee arthroplasty.

N Engl J MedNov 12, 2026Read summary
Clinical ResearchAnesthesiology

Effect of discontinuing antihypertensives on perioperative hypotension in older patients before non-cardiac surgery: multicentre, randomised, double blind, controlled trial.

This multicentre, randomised, double blind, placebo controlled trial assessed whether withholding ACE inhibitors or ARBs on the morning of surgery reduces perioperative hypotension in older adults undergoing non-cardiac…

BMJNov 11, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.